key: cord-0999893-q5t3tnh4
authors: Synolaki, Evgenia; Papadopoulos, Vasileios; Divolis, Georgios; Tsahouridou, Olga; Gavriilidis, Efstratios; Loli, Georgia; Gavriil, Ariana; Tsigalou, Christina; Tziolos, Nikolaos R; Sertaridou, Eleni; Kalra, Bhanu; Kumar, Ajay; Rafailidis, Petros; Pasternack, Arja; Boumpas, Dimitrios T; Germanidis, Georgios; Ritvos, Olli; Metallidis, Simeon; Skendros, Panagiotis; Sideras, Paschalis
title: The Activin/Follistatin-axis is severely deregulated in COVID-19 and independently associated with in-hospital mortality
date: 2021-02-24
journal: J Infect Dis
DOI: 10.1093/infdis/jiab108
sha: d399bd336308d2d97d18cfeaf7f2faef80472368
doc_id: 999893
cord_uid: q5t3tnh4

BACKGROUND: Activins are members of the TGFβ-superfamily implicated in the pathogenesis of several immuno-inflammatory disorders. Based on our previous studies demonstrating that over-expression of Activin-A in murine lung causes pathology sharing key features of COVID-19, we hypothesized that Activins and their natural inhibitor Follistatin might be particularly relevant to COVID-19 pathophysiology. METHODS: Activin-A, Activin-B and Follistatin levels were retrospectively analyzed in 574 serum samples from 263 COVID-19 patients hospitalized in three independent centers, and compared with common demographic, clinical and laboratory parameters. Optimal-scaling with ridge-regression was used to screen variables and establish a prediction model. RESULT: The Activin/Follistatin-axis was significantly deregulated during the course of COVID-19, correlated with severity and independently associated with mortality. FACT-CLINYCoD, a novel disease scoring system, adding one point for each of Follistatin>6235pg/ml, Activin-A>591pg/ml, Activin-B>249pg/ml, CRP>10.3mg/dL, LDH>427U/L, Intensive Care Unit (ICU) admission, Neutrophil/Lymphocyte-Ratio>5.6, Age>61, Comorbidities>1 and D-dimers>1097ng/ml, efficiently predicted fatal outcome in an initial cohort (AUC: 0.951; 95%CI: 0.919-0.983, p<10 (-6)). Two independent cohorts that were used for validation indicated similar AUC values. CONCLUSIONS: This study unravels strong link between Activin/Follistatin-axis and COVID-19 mortality and introduces FACT-CLINYCoD, a novel pathophysiology-based tool that allows dynamic prediction of disease outcome, supporting clinical decision making.

COVID-19 pandemic constitutes presently the most prominent public-health issue worldwide [1] . The disease follows a bimodal pattern. The initial phase of relates to viral pathogenic effects and is characterized by mild "flu-like" symptoms [2] . However, approximately one week after onset-of-symptoms, ~20% of patients develop moderate to severe acute respiratory distress syndrome (ARDS), thereby increasing substantially in-hospital mortality [2] [3] [4] [5] . Various comorbidities and aging negatively affect COVID-19 outcome [3, 6] . Accumulating evidence indicate that excessive activation of innate-immunity, deregulated neutrophils and thrombotic microangiopathy characterize the maladaptive host-response that drives the pathophysiology of severe COVID-19 [7] [8] [9] [10] [11] . These pathomechanisms lead to rapid progression of hypoxemic respiratory failure and protean clinical manifestations that involve almost every organ [12, 13] . Monitoring hospitalized COVID-19 patients, in the midst of multiple continuously changing parameters is challenging [2, 3, 5, 13] .

Therefore, development of novel therapeutic strategies and bed-to-bench tools permitting day-to-day prediction of patient outcome is of utmost importance for such dynamically evolving and clinically heterogeneous disease [12, [14] [15] [16] .

Activin-A and Activin-B are members of the Transforming Growth Factor-β (TGF-β)superfamily implicated in the regulation of numerous aspects of inflammation and/or tissue remodeling [17] [18] [19] . Follistatin, a physiological Activin inhibitor, binds to them, induces endocytosis and proteolytic degradation and modulates their bioavailability [20] . Activins and Follistatin, are synthesized continuously in healthy tissues [21] . However, in immuno-inflammatory conditions, epithelial, endothelial, A c c e p t e d M a n u s c r i p t 5 interstitial stroma cells and immune cells secrete higher levels that can be detected in serum as biomarkers of local or systemic stress [17] [18] [19] .

We have previously described over-expression of Activin-A and Follistatin in bronchoalveolar lavage (BAL) of ARDS patients [18, 22] . Moreover, we showed that ectopic expression of Activin-A in murine lungs causes ARDS-like pathology [22] , which shares cardinal features of COVID-19 pathophysiology. These include, neutrophils infiltration in the lung, alveolar epithelial and endothelial cell damage, systemic hyper-coagulant state and a deregulated cytokine response [5, 7, 8, 18, 23] .

In view of these findings we hypothesized that the Activins might be particularly relevant to To validate this hypothesis, we analyzed sera from COVID-19 patients and found that Activin-A, Activin-B and Follistatin, herein referred to as the Activin-Follistatin-axis (A/F-axis) were significantly upregulated during the crucial period when patients tend to deteriorate. Of note, these A/F-axis components were independently associated with disease severity and in-hospital mortality. Based on that, we developed and validated a scoring-system for prediction and monitoring of COVID-19 outcome in real-life using Activins, Follistatin and common clinical/laboratory parameters.

This is a retrospective study with a single endpoint, the final outcome (survival or death). Three national reference hospitals from distant regions of Greece participated in the study (Supplementary Figure 1A ). An initial cohort of 117 consecutive COVID-19 patients hospitalized at University Hospital, Alexandroupolis and "AHEPA" Hospital, Thessaloniki from March 10, 2020 and had an outcome until A c c e p t e d M a n u s c r i p t 6 July 7, 2020 was endorsed and 314 randomly acquired samples were analyzed (Table   1 and Supplementary Figure 1B) . Two independent validation cohorts belonging to the "second COVID-19 wave" between end of July and early October 2020 were introduced: The first included 28 consecutive COVID-19 patients derived from a distinct hospital ("Attikon" Hospital, Athens) contributing 35 samples and the second included 118 consecutive patients derived from Alexandroupolis and "AHEPA" hospitals contributing 225 samples (Supplementary Table 1 ). Activin-A, Activin-B, Follistatin, and standard-of-care (SOC) laboratory parameters including absoluteneutrophil-count (ANC), absolute-lymphocyte-count (ALC), neutrophil/lymphocyteratio (NLR), C-reactive protein (CRP), lactate dehydrogenase (LDH), ferritin and Ddimers, were analyzed. All laboratory variables were measured concomitantly in serum (or citrated plasma in case of D-dimers) samples derived from the same venipuncture. Measurements of Activins/Follistatin levels were performed with the leftover sera. The study conformed to the TRIPOD statement [24] and is aligned with the Helsinki declaration. The study protocol design was approved by the Local 

Activin-A, Activin-B and Follistatin serum levels were measured using enzyme-linked immunosorbent-assay (ELISA) (Ansh-Labs, Webster, TX, USA) according to manufacturer's instructions.

To elucidate the role of A/F-axis molecules, we carried out an analysis based on samples and not on patients; for that purpose, we initially used three separate general linear models, each one incorporating outcome as binary dependent variable (survival/death), as well as Activin-A, Activin-B, Follistatin and either multiplicity of sampling, or period of sampling, or reference hospital as independent variables to discriminate whether the latter three variables were potential confounders or true predictors. Having validated the prognostic value of A/F-axis molecules as predictors of outcome, we further examined their independent prognostic value across 14 variables of interest, including potential confounders, which were transformed to binary ones through nominal optimal scaling along with discretization to two groups.

Imputing of missing data was added using the CATREG automated selection function of SPSS, ridge-regression was selected for regularization and 10-fold cross-validation was added. Results were adapted to a point-system scoring, where one additive point was given for each parameter included in the unfavorable category as suggested after discretization; binary-regression was utilized to mathematically approach outcome probability. Evaluation of the scoring systems was based on Area-Under-Curve (AUC) as determined from Receiver Operating Characteristic (ROC) analysis. Optimal-Scaling procedure was utilized to detect whether the scoring A c c e p t e d M a n u s c r i p t 8 systems could predict response to certain treatment options. More details regarding the Materials and Methods is provided in Supplementary Materials.

To validate the hypothesis that the A/F-axis is linked to COVID-19 pathophysiology A c c e p t e d M a n u s c r i p t 9 might constitute confounders that blur the results, three discrete general linear models including Activin-A, Activin-B and Follistatin as dependent variables and outcome along with either multiplicity of samples per patient or sampling period (1-7/8-14/15+ day of sampling) or reference hospital as independent ones were introduced. These models demonstrated that Activins and Follistatin did not correlate with any of these potential confounders (Supplementary Table 3 ). Therefore, our efforts to construct a predictive model were based on the analysis of all the samples of the initial cohort rather than the analysis of independent patients.

Thus for subjects where several samples were drawn at different disease stages, each sample was treated as an independent entry and its score was computed separately.

COVID-19 is characterized by clinical heterogeneity and a dynamically changing phenotype [2, 3, 5, 12] . We hypothesized that this behavior must be mirrored by analogous fluctuations in the expression profiles of key biomarkers. We therefore Activin-B and LDH levels. However, patients AL063 and AX112, were characterized by substantial changes in Activin-A, Activin-B and CRP levels and for patients AL035 and AL062 disease progression was associated with eventual CRP and NLR reduction.

Interestingly, patient AL022, who received a dose of Tocilizumab one day after admission, exhibited for ~10 days transient reduction of LDH, CRP, NLR, Activin-A and Activin-B, before reverting and dying on disease-day 28. Therefore, in addition to patient intrinsic phenotypic variability, treatments could also influence biomarker profile during hospitalization. From all the above we concluded that a broader spectrum of biomarkers, including both early and later modulated ones, had to be integrated to develop a meaningful disease scoring/monitoring-system.

Considering the heterogeneous phenotypic changes characterizing COVID-19 progression, we aimed to build a simple and clinically meaningful scoring system to discriminate survivors from non-survivors. To this end, we first demonstrated that Follistatin, Activin-A, Activin-B, CRP, LDH, ICU-admittance, NLR, age, comorbidities and D-dimers performed well in predicting disease outcome, as judged by ROC analysis (Supplementary Figure 4) . Notably, among all these parameters, Follistatin A c c e p t e d M a n u s c r i p t 11 exhibited the highest AUC (0.857). We then converted all these continuous variables, which could independently predict outcome, to binary through selection of optimal cutoffs using optimal-Scaling procedure along with ridge-regression (Supplementary   Figure 5 and Supplementary Table 4 ). Based on these data, we constructed a tenpoint scoring-system where one additive point was arbitrarily given for each parameter included in the unfavorable category as suggested after discretization, namely if Follistatin>6235 pg/ml, Activin-A>591 pg/ml, Activin-B>249 pg/ml, Considering that various treatment modalities might affect the value of FACT-CLINYCoD score to predict final outcome, we performed ROC analysis separately for samples corresponding to each treatment (Supplementary Figure 6) . Interestingly, all relevant AUCs were similar, thus indicating that the predictive value of FACT-CLINYCoD score was not affected by current therapies. Therefore, this scoring system may be used for monitoring response to treatment.

The FACT-CLINYCoD score was at first validated using an independent cohort of 28 consecutive patients contributing 35 random samples. Although this small cohort differed significantly from the initial regarding mortality rate, age, disease-status, treatments, sampling approach, and day-from-disease-onset (Supplementary Table   1 ), a similar AUC was observed (0.958, 95%CI: 0.872-1.000, P=0.032, Figure 4A) . A second independent validation cohort of 118 consecutive patients contributing 225 samples, differing significantly regarding sex-ratio, number of comorbidities, diseasestatus, treatments, and sampling approach (Supplementary Table 1 ) was again found to exhibit an AUC of 0.924 (95%CI: 0.890 -0.958, P<10 -6 , Figure 4A ). Both validation cohorts shared similar AUCs with the initial cohort (P=0.880 and 0.256, respectively).

To further substantiate the significance of Activins and Follistatin for the predictive power of the FACT-CLINYCoD scoring system we performed an ad-hoc analysis in all 574 samples derived from both initial and validation cohorts using area under A c c e p t e d M a n u s c r i p t 13 precision-recall curves (AUPRC) (Supplementary data). As a result, we found that FACT-CLINYCoD score is superior to the "F/A axis-depleted (CLINYCoD) score; the difference between the relevant AUPRCs is 4.8% (95% CI: 2.6%-7.5%), P<0.05 (Supplementary Figure 7A) . Moreover, FACT-CLINYCoD score is even superior to "Activins-depleted" (F-CLINYCoD) score; the difference between the relevant AUPRCs is 1.5% (95% CI: 0.3%-3.2%), P<0.05 (Supplementary Figure 7B) . These results demonstrate the contribution of all three A/F-axis proteins in the predictive power of the FACT-CLINYCoD scoring system.

Optimal-Scaling procedure was performed along with ridge-regression to investigate whether FACT-CLINYCoD score could guide timely administration of current SOC treatments [25] such as low-molecular-weight heparin (LMWH), remdesivir and 

This study provides evidence suggesting that inflammation and tissue stress-related proteins Activin-A, Activin-B, and Follistatin (A/F-axis) are tightly associated with severity and outcome of COVID-19. Their upregulation was prominent in nonsurvivors and was independently related to in-hospital mortality. Of note, combination of A/F-axis components with common clinical and laboratory parameters permits prediction of COVID-19 outcome throughout the course of the disease.

Identification of high-risk patients and death-prediction are of particular importance especially in strained health-care systems. Hence, several studies attempted to develop scoring systems to predict timely disease severity and mortality [4, 6, 14, 15, [26] [27] [28] . Most of these models were based on demographic parameters and instantaneous evaluation of subjective symptoms (i.e. dyspnea) combined with single measurements of common laboratory markers, such as neutrophil or lymphocyte counts, LDH, CRP and several proinflammatory cytokines [4, 6, 14, 15, 26, 28, 29] . These models are undoubtedly useful; however, they emphasize prediction of final-outcome at admission and thus may fail to predict some non-survivors most likely due to the complex and often erratic development of COVID-19 and the downregulation of key biomarkers at late disease-stages ( Figure 3 and Supplementary Figure 3 ).

Considering the above, we exploited the findings presented herein to develop a more dynamic COVID-19 monitoring-system. Specifically, we utilized the measurement of Activin and Follistatin levels, based on their deregulation described herein and their previous implication in sepsis/ARDS, neutrophil-mediated A c c e p t e d M a n u s c r i p t 15 inflammation, coagulopathy, endothelial cell stress, angiogenesis and postinflammatory pulmonary fibrosis/remodeling, all of which are key characteristics of COVID-19 pathophysiology [7, 8, 18, 22, 30] . Moreover, we reasoned that upregulation of A/F-axis could indicate tissue-damage in the lung, vasculature or other vital peripheral tissues, thus complementing information derived from other biomarkers reporting tissue-damage (i.e. LDH) or coagulation/vascular injury (i.e. D-dimers) [2, 15, 27, 28] . Finally, taking into consideration the differences in kinetics of A/F-axis components and other clinical biomarkers like NLR, CRP, LDH and D-dimers ( Figure 2) we combined them all to develop a more generalizable monitoring-system that will not only make early predictions but will rather allow readjustment of predictions during disease progress [31] .

In the pre-COVID-19 era, the A/F-axis was evaluated as predictor of outcome in critical-care patients [32] . Increased levels of Activin-A and Activin-B in sera from ICU patients with acute respiratory failure could predict 90-days and 12-months survival with reasonable accuracy (~80%). Follistatin did not provide any extra predictive value [32] . A/F-axis components were measured also in critically-ill, influenza-A (H1N1), patients, but no significant association with disease severity was established [33] . However, while preparing the current manuscript, consistent with our conclusions, a preprint study reported Follistatin among the circulating markers of endothelial damage associated with in-hospital mortality in a small number of COVID-19 patients [34] .

Although the exact mechanism linking Activins to COVID-19 pathogenesis remains unknown, the importance of A/F-axis in the disease is reflected on the predictive value of FACT-CLINYCoD score, the superiority of which was demonstrated by the ad-A c c e p t e d M a n u s c r i p t 16 hoc analysis vs the "F/A axis-depleted" CLINYCoD and "Activin-depleted" F-CLINYCoD scores (Supplementary Figure 7A,B) . The FACT-CLINYCoD model, which depends on A/F-axis by 3/10, demonstrates an almost perfect AUC (0.951±0.032) as well as a very satisfactory sensitivity (81.5%) and specificity (95.7%) of scores ≥5 to predict fatal outcome. In agreement with this, the key role of A/F-axis components, in particular Follistatin, in the prediction of fatal outcome at any time of disease course ( Figure 4B,C) is underlined by the relevant ROC analysis (Supplementary Figure 4) and ridge-regression (Supplementary Figure 5) . The FACT-CLINYCoD score constitutes a balanced, robust and flexible tool efficiently intertwining pathophysiology of A/Faxis, clinical profile (by means of NLR, LDH, D-dimers and CRP) and key parameters that are well established to affect mortality (ICU admission, age, and comorbidities), capable of providing dynamic outcome prediction.

An obvious emerging question is whether the A/F-axis is a suitable target for COVID-19 therapeutics. Indeed, several studies have proposed Follistatin or soluble Activin type-II receptors as therapeutics for sepsis, ARDS and fibrotic disorders [18, 35] .

Although increase of Activin-A and -B could be interpreted in favor of utilizing such therapeutics, the dramatic increase of Follistatin, often at stoichiometry that surpasses substantially the sum of Activins-A and -B in serum, could argue against it.

Neutrophils can release preformed Activin-A upon arrival in inflamed tissues [18, 36] , whereas, other inflammatory cells such as monocytes, CD4 + T cells and tissue resident cells can secrete Activin-A later on [18, 21, 37] . Neutrophils do not secrete Activin-B and therefore this factor must be produced by other cells, probably acting as a biomarker of vascular stress and hypoxia [38, 39] . Follistatin can be produced locally or released systemically from distant organs such as liver [18] . The tissue M a n u s c r i p t 17 origin of the increased A/F-axis components in sera of COVID-19 patients and the actual Activin/Follistatin stoichiometry in the affected tissues are unknown.

Therefore, the suitability of the A/F-axis as therapeutic target for COVID-19 warrants further careful investigation.

Another promising aspect of this study is the potential utility of FACT-CLINYCoD to monitor response to various treatments targeting SARS-CoV-2 (antivirals) or hyperinflammatory host reactions (heparin, corticosteroids) since the value of this scoring system to predict mortality was not disturbed by various treatments. Our preliminary results showed favorable outcome when LMWH and dexamethasone was commenced at FACT-CLINYCoD score ≤2. This is consistent with emerging clinical data linking reduced mortality with early administration of LMWH in all hospitalized COVID-19 patients [40] and supports the detrimental role of immunothrombosis in COVID-19 [7] . Moreover, current clinical data derived from randomized clinical studies recommend administration of dexamethasone as early as the patient needs oxygen supply [25] .

Finally, the postulated implication of the A/F-axis in other infectious diseases associated with in-hospital mortality [17] [18] [19] 22] , leaves open the possibility that the FACT-CLINYCoD score may be applicable to other diseases in addition to COVID-19.

Overall, potential limitations of this study could be considered. First, the possible inherent weaknesses due to the retrospective nature of our findings, although they were well-validated. Second, the applicability of the FACT-CLINYCoD score requires the implementation of Activins/Follistatin measurements in daily laboratory routine. M a n u s c r i p t 18 In conclusion, A/F-axis dysregulation is tightly associated with poor outcome of COVID-19. FACT-CLINYCoD, a novel pathophysiology-driven monitoring-system, enables dynamic prediction of disease outcome and may support real-time medical decision. Prospectively, large-scale, multinational validation of this calculator, as well as investigation of the mechanisms linking A/F-axis to COVID-19 pathogenesis is definitely warranted. A c c e p t e d M a n u s c r i p t 30 Figure 4 

WHO Coronavirus Disease (COVID-19) Dashboard. Available at

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area

Interleukin-6-based mortality risk model for hospitalised COVID-19 patients

COVID-19: consider cytokine storm syndromes and immunosuppression

Age and Multimorbidity Predict Death Among COVID-19 Patients: Results of the SARS-RAS Study of the Italian Society of Hypertension

Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19

Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

Uncontrolled Innate and Impaired Adaptive Immune Responses in Patients with COVID-19 ARDS

Extrapulmonary manifestations of COVID-19

Severe Covid-19

Association between markers of immune response at hospital admission and COVID-19 disease severity and mortality: A meta-analysis and meta-regression

Prediction models for diagnosis and prognosis of covid-19 infection: systematic review and critical appraisal

COVID-19 conundrum: Clinical phenotyping based on pathophysiology as a promising approach to guide therapy in a novel illness

Activin A and follistatin in systemic inflammation

Activin, neutrophils, and inflammation: just coincidence?

Activins and Inhibins: Roles in Development, Physiology, and Disease

The structure of the follistatin:activin complex reveals antagonism of both type I and type II receptor binding

The tissue distribution of activin beta Aand beta B-subunit and follistatin messenger ribonucleic acids suggests multiple sites of action for the activin-follistatin system during human development

Activin-A overexpression in the murine lung causes pathology that simulates acute respiratory distress syndrome

The evolution of pulmonary pathology in fatal COVID-19 disease: an autopsy study with clinical correlation

Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): The TRIPOD Statement

Information on COVID-19 Treatment, Prevention and Research

Development and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients With COVID-19

Scoring systems for predicting mortality for severe patients with COVID-19

An interpretable mortality prediction model for COVID-19 patients

An inflammatory cytokine signature predicts COVID-19 severity and survival

Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy

The inherent problems with the generalizability of the CALL score: towards reliable clinical prediction models for COVID-19

Serum activin A and B levels predict outcome in patients with acute respiratory failure: a prospective cohort study

Serum activin A and B, and follistatin in critically ill patients with influenza A(H1N1) infection

Circulating Markers of Angiogenesis and Endotheliopathy in COVID-19

The activins and their binding protein, follistatin-Diagnostic and therapeutic targets in inflammatory disease and fibrosis

Activin A is a critical component of the inflammatory response, and its binding protein, follistatin, reduces mortality in endotoxemia

The roles of activin A and its binding protein, follistatin, in inflammation and tissue repair

Key role for activin B in cellular transformation after loss of the von Hippel-Lindau tumor suppressor

Activin inhibition limits early innate immune response in rat kidney allografts-a pilot study

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

A c c e p t e d M a n u s c r i p t 20 A c c e p t e d M a n u s c r i p t 22